StreetInsider.com News Articles

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

SHANGHAI, Aug. 17, 2026 /PRNewswire/ -- On August 17, 2026, Shanghai Henlius Biotech, Inc. (2696.HK) announced that it has entered into a strategic collaboration with Sandoz (SIX: SDZ; OTCQX: SDZNY), a global leader in generics and

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Mon, 17 Aug 2026 00:08:00 -0400

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
The collaboration further expands the parties' 2025 oncology biosimilars partnership

Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US

Wed, 24 Sep 2025 16:15:00 -0400

Expands access to much-needed iron therapy for millions of US patients
Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches
Strengthens US supply of injectable iron sucrose

PRINCETON, N.J.--(BUSINESS WIRE)-- Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA)1. The product is now available for order and delivery across the United States. The launch of this iron sucrose formulation further expands the Sandoz US iron therapy portfolio.

Intravenous iron sucrose is

Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US

Wed, 24 Sep 2025 16:15:00 -0400

Expands access to much-needed iron therapy for millions of US patients
Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches
Strengthens US supply of injectable iron sucrose

Intravenous iron sucrose is

Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US

Wed, 24 Sep 2025 16:15:00 -0400

Expands access to much-needed iron therapy for millions of US patients
Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches
Strengthens US supply of injectable iron sucrose

Intravenous iron sucrose is

Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US

Wed, 24 Sep 2025 16:15:00 -0400

Expands access to much-needed iron therapy for millions of US patients
Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches
Strengthens US supply of injectable iron sucrose

Intravenous iron sucrose is

Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US

Wed, 24 Sep 2025 16:15:00 -0400

Expands access to much-needed iron therapy for millions of US patients
Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches
Strengthens US supply of injectable iron sucrose

Intravenous iron sucrose is

Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US

Wed, 24 Sep 2025 16:15:00 -0400

Expands access to much-needed iron therapy for millions of US patients
Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches
Strengthens US supply of injectable iron sucrose

Intravenous iron sucrose is

Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US

Wed, 24 Sep 2025 16:15:00 -0400

Expands access to much-needed iron therapy for millions of US patients
Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches
Strengthens US supply of injectable iron sucrose

Intravenous iron sucrose is